fda regulations on semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know Hims & Hers stock falls

"Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss"

The implications extend beyond obesity and diabetes to every class B GPCR target in the human genome, suggesting that many receptors previously considered "undruggable" by small molecules may be amenable to similar approaches

Our growing network of journalists in Africa, Asia, Geneva and New York connect the dots between regional realities and the big global debates, with evidence-based, open access news and analysis

How to get WEGOVY injection delivered in India

What the comparison actually tells you Comparing medications side by side helps clarify options, but it doesn't make the decision for you

The longer-term BALANCE Model, expected to begin in January 2027 through participating Part D plans, is still being finalized